Cognyte Software (NASDAQ:CGNT – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of -0.070–0.070 for the period, compared to the consensus EPS estimate of -0.120. The company issued revenue guidance of $337.1 million-$350.9 million, compared to the consensus revenue estimate of $339.0 million. Cognyte Software also updated its FY25 guidance to ($0.07) EPS.
Cognyte Software Stock Down 6.6 %
NASDAQ:CGNT traded down $0.53 during trading hours on Tuesday, hitting $7.48. 467,913 shares of the stock traded hands, compared to its average volume of 363,074. Cognyte Software has a 1 year low of $4.00 and a 1 year high of $8.64. The company has a market cap of $531.23 million, a price-to-earnings ratio of -32.65 and a beta of 1.74. The stock has a 50 day moving average price of $7.37 and a 200 day moving average price of $7.08.
Cognyte Software (NASDAQ:CGNT – Get Free Report) last released its earnings results on Tuesday, April 9th. The medical device company reported ($0.28) EPS for the quarter. Cognyte Software had a negative return on equity of 12.06% and a negative net margin of 4.97%. The company had revenue of $83.69 million during the quarter. Equities analysts forecast that Cognyte Software will post -0.3 earnings per share for the current fiscal year.
Analyst Ratings Changes
Check Out Our Latest Report on Cognyte Software
Cognyte Software Company Profile
Cognyte Software Ltd. provides an investigative analytics software to governments and enterprises worldwide. Its Actionable Intelligence for a Safer World, an open software designed to help governments and enterprises accelerate and enhance the effectiveness of investigations. The company offers network intelligence analytics, threat intelligence analytics, decision intelligence analytics, and operational intelligence analytics solutions.
Further Reading
- Five stocks we like better than Cognyte Software
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Occidental Stock: Buffett’s 9-Day Buying Spree Lifts Stake to 29%
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3M Stock: Invest Now for Unmatched Quality and Growth Potential
- Quiet Period Expirations Explained
- Super Micro AI Stock: Should You Invest After a 275% Increase?
Receive News & Ratings for Cognyte Software Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognyte Software and related companies with MarketBeat.com's FREE daily email newsletter.